The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.

The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

A method of diagnosing Parkinson's disease uses the abnormal concentrations of a group of 21 blood serum protein biomarkers. The concentration of the 21 protein biomarkers is assessed in a patient's serum by quantitative two-dimensional polyacrylamide gel electrophoresis.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.